Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District

Core Insights - Eli Lilly and Company announced plans to invest an additional $5.3 billion in the LEAP Research and Innovation District, bringing total investment to $9 billion, aimed at enhancing manufacturing capacity for type 2 diabetes and obesity medicines [1][3] - The investment will create 200 new full-time jobs, increasing total planned new jobs at LEAP to 900, focusing on skilled positions such as engineers and scientists [2][5] - This expansion is noted as the largest manufacturing investment in the company's history and potentially the largest in synthetic medicine API manufacturing in the U.S. [3] Investment and Economic Impact - Since 2020, Eli Lilly has committed over $16 billion to new manufacturing sites in the U.S. and Europe, with significant investments in locations outside Indiana [3] - The Indiana Economic Development Corporation (IEDC) is providing up to $500,000 in training grants, $20 million in redevelopment tax credits, and $15 million for road infrastructure improvements related to the new investment [5] - The total estimated capital investment at the LEAP site is projected to reach $9.7 billion, with a 30-year benefit period for tax rebates valued at approximately $1.2 billion [5] Workforce Development - The state of Indiana is collaborating with Eli Lilly to develop a workforce training center to support the manufacturing talent ecosystem [4] - This initiative aligns with Lilly's financial support for scholarship and training programs at local educational institutions [4]